COVID-19 and solid organ transplant recipients [COVID-19]
Research type
Research Study
Full title
Impact, feasibility and outcomes of shielding for novel coronavirus in (immunosuppressed) solid organ transplant recipients
IRAS ID
284408
Contact name
Hermien Hartog
Contact email
Sponsor organisation
UHB NHS foundation trust
Duration of Study in the UK
1 years, 0 months, 9 days
Research summary
The international spread of a novel coronavirus, SARS-CoV-2, has led to a global pandemic. Particular groups are considered to be more vulnerable to the effect of COVID-19 and these include individuals who have previously received solid organ transplants (SOT). Due to this additional risk, these individuals have been instructed by Public Health England to undergo a process “of shielding”. This is a a stricter form of self-isolation in which they are not exposed to any other person for an extended period. The incidence of COVID-19 in SOT recipients and the outcome of infection is largely unknown at present. In addition, the psychological impact of “shielding” has not been investigated. The study objective is to explore both the quantitative and qualitative effects of shielding for immunosuppressed solid organ transplant recipients during the COVID-19 pandemic and determine a patient reported incidence of infection.\n\n
REC name
London - Bloomsbury Research Ethics Committee
REC reference
20/HRA/2613
Date of REC Opinion
8 Jun 2020
REC opinion
Favourable Opinion